Coverage Initiation Report Focuses on Oramed Pharmaceuticals

//Coverage Initiation Report Focuses on Oramed Pharmaceuticals

Coverage Initiation Report Focuses on Oramed Pharmaceuticals

NEW YORK, NY — (Marketwired) — 11/11/14
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is the subject of a new in-depth initiation coverage repot by Acceleron Equity Research.

Interested investor may get more information and a copy of the coverage report at:

  • On November 3, 2014 ORMP announced very favorable top-line results from a Phase 2a trial for its oral insulin capsule in ORMD-0801 for Type 1 diabetes, addressing the multi-billion dollar diabetes market.
  • ORMP’s unique Protein Oral Delivery (POD™) technology is a breakthrough in medical science that enables small proteins to travel through the gastrointestinal tract, via the liver, and into the bloodstream to treat a broad number of indications including diabetes.
  • POD technology addresses a market of roughly $50 billion worth of drugs and vaccines that are currently delivered via injections. This includes diabetes, the first indication pursued by OMRP, a market where $20 billion worth insulin was sold globally in 2013.
  • The Company’s ORMD-0801 oral insulin capsule has the potential to create a new paradigm in the treatment of Type 2 diabetes by treating the disease at an earlier stage, thereby slowing its progression. Having completed a successful FDA Phase 2a trial in Type 2 diabetes, ORMP is now planning its Phase 2b trial for Type 2 diabetes.
  • ORMD-0901, an oral GLP-1 analog, addressing an annual $2 billion market is expected to enter Phase 1b trials in Israel by the end of 2014. In Q3 of 2013 ORMP submitted a Pre-IND package to the U.S. FDA. ORMP expects to begin a Phase II multi-center study for ORMD-0901 in Q3-2015.

About Acceleron Equity Research
Acceleron is a market intelligence service that focuses on identifying and analyzing technically-complicated companies and equities. Acceleron offers a subscription model product to investors and funds with an emphasis in the emerging markets.

Media Contact:
Mike Morhamus
Acceleron Equity Research

Source: Oramed Pharmaceuticals

2018-05-30T17:04:25+00:00 Categories: Press Releases|Tags: |